EGFR and neoplasm: The presence of detectable cfDNA mutations (such as in TP53) not being represented in tumor supports a role for cfDNA whereas our findings of genomic alterations (including PIK3CA and EGFR) being detected robustly in tumor tissue sampling but not represented in cfDNA fractions cautions against complete abandonment of tumor tissue sequencing.